Oryzon Genomics (ORYE) Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ORYE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.86 |
| 52 Week High | €3.58 |
| 52 Week Low | €2.68 |
| Beta | 0.49 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | 5.92% |
| Change since IPO | -38.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORYE | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.5% | -3.9% |
| 1Y | n/a | 16.3% | 16.3% |
Return vs Industry: Insufficient data to determine how ORYE performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ORYE performed against the UK Market.
Price Volatility
| ORYE volatility | |
|---|---|
| ORYE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ORYE's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ORYE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 47 | Carlos Manuel Arjol | www.oryzon.com/en |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others.
Oryzon Genomics S.A. Fundamentals Summary
| ORYE fundamental statistics | |
|---|---|
| Market cap | €235.77m |
| Earnings (TTM) | -€2.79m |
| Revenue (TTM) | €7.45m |
Is ORYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORYE income statement (TTM) | |
|---|---|
| Revenue | US$8.63m |
| Cost of Revenue | US$354.56k |
| Gross Profit | US$8.28m |
| Other Expenses | US$11.51m |
| Earnings | -US$3.23m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 95.89% |
| Net Profit Margin | -37.45% |
| Debt/Equity Ratio | 15.8% |
How did ORYE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 06:27 |
| End of Day Share Price | 2025/11/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oryzon Genomics S.A. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Arron Aatkar | Edison Investment Research |
| Joaquin Garcia-Quiros | JB Capital Markets |